ABSTRACT
Performances of the new automatic system COBAS AmpliPrep/COBAS TaqMan 48 (CAP/CTM) (Roche, Branchburg, NJ) for HBV DNA extraction and real-time PCR quantification were assessed and compared with the endpoint PCR COBAS AMPLICOR HBV Monitor (CAHBM, Roche). Analytical evaluation with proficiency panels from UK National External Quality Assessment Scheme (UK NEQAS) over a 1-year period of distribution showed that CAP/CTM correctly measured HBV DNA levels with a close correlation between expected and observed values (r=0.995). Clinical evaluation as tested with samples from 11 HBsAg-positive patients undergoing antiviral therapy (71 serial specimens of plasma), demonstrated excellent correlation with CAHBM (r=0.958, mean difference in quantitation: 0.14 log, IU/ml), but CAP/CTM detected longer period of residual viremia. HBV DNA reduction was much higher in the combination schedule (Lamivudine+Adefovir), than in Adefovir monotherapy (5.1 vs. 3.5 logs). In conclusion, CAP/CTM allows for an accurate and standardized quantification of HBV DNA in high through-put laboratories. Due to it high sensitivity, it may further improve the detection of emerging drug resistance strains and the assessment of antiviral therapy.
Subject(s)
Antiviral Agents/therapeutic use , DNA, Viral/blood , Hepatitis B virus/drug effects , Hepatitis B virus/isolation & purification , Hepatitis B, Chronic/drug therapy , Hepatitis B, Chronic/virology , Polymerase Chain Reaction/methods , Adenine/analogs & derivatives , Adenine/therapeutic use , Automation , DNA, Viral/analysis , DNA, Viral/isolation & purification , Hepatitis B Surface Antigens/blood , Hepatitis B virus/genetics , Humans , Lamivudine/therapeutic use , Organophosphonates/therapeutic use , Taq PolymeraseABSTRACT
Success in antiviral therapy for chronic hepatitis B is supported by highly sensitive PCR-based assays for hepatitis B virus (HBV) DNA. Nucleic acid extraction from biologic specimens is technically demanding, and reliable PCR results depend on it. The performances of the fully automatic system COBAS AmpliPrep-COBAS TaqMan 48 (CAP-CTM; Roche, Branchburg, NJ) for HBV DNA extraction and real-time PCR quantification were assessed and compared to the endpoint PCR COBAS AMPLICOR HBV monitor (CAHBM; Roche). Analytical evaluation with a proficiency panel showed that CAP-CTM quantitated HBV DNA levels in one single run over a wide dynamic range (7 logs) with a close correlation between expected and observed values (r = 0.976, interassay variability below 5%). Clinical evaluation, as tested with samples from 92 HBsAg-positive patients, demonstrated excellent correlation with CAHBM (r = 0.966, mean difference in quantitation = 0.36 log(10) IU/ml). CAP-CTM detected 10% more viremic patients and longer periods of residual viremia in those on therapy. In lamivudine (LAM)-resistant patients, the reduction of HBV DNA after 12 months of Adefovir (ADF) was higher in the combination (LAM+ADF) schedule than in ADF monotherapy (5.1 logs versus 3.5 logs), suggesting a benefit in continuing LAM. CAP-CTM detected HBV DNA in liver biopsy samples from 15% of HBsAg-negative, anti-HBcAg-positive graft donors with no HBV DNA in plasma. The amount of intrahepatic HBV DNA was significantly lower in occult HBV infection than in overt disease. CAP-CTM can improve the management of HBV infection and the assessment of antiviral therapy and drug resistance, supporting further insights in the emerging area of occult HBV infection.
Subject(s)
DNA, Viral/blood , Hepatitis B virus/isolation & purification , Hepatitis B, Chronic/virology , Polymerase Chain Reaction/methods , Viremia/virology , Adenine/analogs & derivatives , Adenine/therapeutic use , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , Automation , Biopsy , DNA, Viral/analysis , DNA, Viral/isolation & purification , Drug Resistance, Viral , Hepatitis B Surface Antigens/blood , Hepatitis B virus/drug effects , Hepatitis B virus/genetics , Humans , Lamivudine/pharmacology , Lamivudine/therapeutic use , Liver/virology , Nucleic Acid Amplification Techniques , Organophosphonates/therapeutic use , Sensitivity and Specificity , Taq PolymeraseABSTRACT
The focus of this work is on the nitrogen starvation stress responses operating in a plant symbiotic fungus. A cDNA array profiling analysis was conducted on N-limited mycelia of the mycorrhizal ascomycete Tuber borchii. Fifty-one unique transcripts, out of 2062 redundant arrayed cDNAs, were differentially expressed by at least 1.5-fold in response to N deprivation. Only two N assimilation components-a nitrate transporter and a high-affinity ammonium transporter-were found among differentially expressed genes. All the other N status responsive genes code for as yet unidentified hypothetical proteins or components not directly involved in N assimilation or metabolism, especially carbohydrate binding proteins and oligosaccharide as well as lipid modifying enzymes. A subset of cDNA array data were confirmed and extended by Northern blot analysis, which showed that most of the latter components respond not only to nitrogen, but also to carbon source depletion.
Subject(s)
Ascomycota/genetics , Fungal Proteins/genetics , Gene Expression Profiling , Gene Expression Regulation, Fungal , Nitrogen/metabolism , Amino Acid Sequence , Amino Acids/metabolism , Ascomycota/metabolism , Base Sequence , Carbohydrate Metabolism/genetics , Lipid Metabolism/genetics , Molecular Sequence Data , Oligonucleotide Array Sequence Analysis , Promoter Regions, Genetic/geneticsABSTRACT
cDNA arrays were used to explore mechanisms controlling fruiting body development in the truffle Tuber borchii. Differences in gene expression were higher between reproductive and vegetative stage than between two stages of fruiting body maturation. We suggest hypotheses about the importance of various physiological processes during the development of fruiting bodies.